Literature DB >> 6991534

Headache as a model for assessing mild analgesic drugs.

B von Graffenried, R C Hill, E Nüesch.   

Abstract

A method for the evaluation of the efficacy of mild analgesic drugs in outpatients with nonmigrainous headache is described. During the 3-hour drug evaluation period, patients were required to record at hourly intervals their pain intensity using both a verbal rating and a visual analog scale, their pain relief, and the occurrance of side effects. The results obtained in six studies consisted of comparisons of reference compounds aspirin (1000 mg) and two analgesic combinations (containing aminophenazone, caffeine, and butalbital); test medications aspirin (500 mg), codeine (30 mg), proquazone (300 mg), and new formulations of the two analgesic combinations (aminophenazone replaced by propyphenazone); and, in every study, placebo. In a seventh study, the analgesic effects of three doses aspirin (250, 500, and 1000 mg) were compared with that of placebo. Every study was conducted under double-blind, complete crossover conditions, and between 24 and 36 patients were used in each study. Using parametric and nonparametric statistical analyses, the reference compounds and the majority of the test medications exhibited significant analgesic properties. Also, a highly significant dose--response effect was demonstrated for aspirin. It is concluded that the headache model is a practicable, reliable, and sensisive method for the evaluation of the effectiveness of mild analgesic drugs.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6991534     DOI: 10.1002/j.1552-4604.1980.tb02535.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  3 in total

Review 1.  Aspirin for acute treatment of episodic tension-type headache in adults.

Authors:  Sheena Derry; Philip J Wiffen; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2017-01-13

Review 2.  Proquazone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases and pain states.

Authors:  S P Clissold; R Beresford
Journal:  Drugs       Date:  1987-05       Impact factor: 9.546

Review 3.  Should butalbital-containing analgesics be banned? Yes.

Authors:  William B Young; Hua Chiang Siow
Journal:  Curr Pain Headache Rep       Date:  2002-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.